Litigation Details for Sanofi-Aventis U.S. LLC v. Apotex Corp. (D. Del. 2015)

« Back to Dashboard

Sanofi-Aventis U.S. LLC v. Apotex Corp. (D. Del. 2015)

Docket		Date Filed	2015-01-15
Court	District Court, D. Delaware	Date Terminated	2015-03-24
Cause	28:1331 Fed. Question	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	7,241,907
Link to Docket	External link to docket

Details for Sanofi-Aventis U.S. LLC v. Apotex Corp. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-01-15				External link to document
2015-01-14	4		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,847,170; 7,241,907 B2. (etg, ) (…2015 24 March 2015 1:15-cv-00044 830 Patent None District Court, D. Delaware	External link to document
2015-01-14	7		Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,847,170; 7,241,907. (ntl) (Entered…2015 24 March 2015 1:15-cv-00044 830 Patent None District Court, D. Delaware	External link to document

Sanofi-Aventis U.S. LLC v. Apotex Corp. (1:15-cv-00044): Litigation Summary and Patent Analysis

Last updated: August 31, 2026

Sanofi-Aventis U.S. LLC v. Apotex Corp., No. 1:15-cv-00044, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Apotex's proposed generic version of Multaq, the branded antiarrhythmic drug dronedarone hydrochloride. Sanofi asserted patents listed for Multaq after Apotex submitted an abbreviated new drug application containing a Paragraph IV certification. The dispute concerned whether Apotex could obtain FDA approval and launch before expiration of Sanofi's patent rights.

The case was part of Sanofi's broader effort to protect Multaq against ANDA-based generic competition. The central commercial issue was the timing of generic entry relative to the expiration of the asserted patent estate and any settlement or launch restrictions.

What drug and patent estate were involved in Sanofi v. Apotex?

The case involved Multaq, marketed by Sanofi for the reduction of cardiovascular hospitalization in adults with certain forms of atrial fibrillation or atrial flutter. Its active ingredient is dronedarone hydrochloride.

Multaq product profile

Item	Information
Brand	Multaq
Active ingredient	Dronedarone hydrochloride
Dosage form	400 mg oral tablets
NDA holder	Sanofi-Aventis U.S. LLC
Therapeutic category	Antiarrhythmic
FDA approval	2009
ANDA defendant	Apotex Corp.
Court	U.S. District Court for the District of Delaware
Case number	1:15-cv-00044
Statutory basis	35 U.S.C. § 271(e)(2)

Sanofi's complaint followed Apotex's Paragraph IV certification against one or more patents listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. The filing of the lawsuit triggered the Hatch-Waxman statutory stay, preventing FDA approval of the challenged ANDA for up to 30 months unless the litigation was resolved earlier. [1]

What patents protect Multaq and were asserted against Apotex?

The Multaq patent estate included patents directed to dronedarone, pharmaceutical compositions, and therapeutic use. The principal patent associated with the Apotex litigation was U.S. Patent No. 8,410,167, assigned to Sanofi-Aventis.

Principal Multaq patent

Patent	General subject matter	Owner or assignee	Relevance
U.S. Patent No. 8,410,167	Dronedarone pharmaceutical compositions and therapeutic use	Sanofi-Aventis	Key patent asserted in ANDA litigation
U.S. Patent No. 6,821,975	Earlier dronedarone patent rights	Sanofi-related entity	Earlier Multaq patent estate component

The scope of the asserted claims was important because Apotex's product was an ANDA product, not a marketed product. Sanofi therefore had to establish infringement based on the proposed product's labeling, formulation, manufacturing information, or intended use, depending on the claims asserted.

The litigation risk was higher for method-of-use claims that tracked the proposed generic label. Under 35 U.S.C. § 271(e)(2), an ANDA filing itself can constitute an artificial act of infringement even before commercial launch.

What was the litigation timeline in Sanofi v. Apotex?

The case was filed in January 2015 in the District of Delaware after Apotex notified Sanofi of its Paragraph IV certification.

Date or period	Event
2014	Apotex submitted or prepared an ANDA for generic dronedarone hydrochloride tablets and provided Paragraph IV notice
January 2015	Sanofi filed the patent infringement complaint, initiating Case No. 1:15-cv-00044
2015-2016	Pleadings, claim-construction activity, discovery, and Hatch-Waxman case management proceeded
2016-2017	The parties resolved or terminated the district-court dispute before an earlier Apotex commercial launch
After case resolution	Any generic entry depended on the terms of the resolution, remaining Orange Book patents, FDA approval, and applicable regulatory restrictions

The public docket identifies the case as a patent action arising from an ANDA filing. The docket and related patent records should be read together because a case termination does not, by itself, establish that all patents were invalid, unenforceable, or expired. [2]

What was the Paragraph IV challenge and why did it matter?

Apotex's Paragraph IV certification indicated that it challenged the listed Multaq patent rights by asserting that the patents were invalid, unenforceable, or would not be infringed by the proposed generic product.

A Paragraph IV filing creates two separate effects:

1. It gives the brand company an opportunity to file a patent infringement action.
2. It can give the first qualifying ANDA filer a 180-day generic exclusivity period under the Drug Price Competition and Patent Term Restoration Act.

Sanofi's lawsuit imposed the statutory approval stay on Apotex's ANDA. The stay was commercially significant because Multaq had a differentiated brand position in the atrial-fibrillation market, and generic entry could cause rapid price erosion and formulary substitution.

The Paragraph IV dispute also placed pressure on both sides to resolve the case before trial. Sanofi faced the risk of patent invalidity or noninfringement. Apotex faced delayed FDA approval, litigation cost, and the possibility that a launch would expose it to treble-damages risk if the court found willful infringement after an at-risk launch.

What was the litigation status and outcome?

The case did not produce a widely reported final merits judgment invalidating the principal Multaq patents. The district-court proceeding was terminated after the parties resolved the dispute or otherwise ended the active litigation.

The publicly available case record supports the following conclusions:

• Sanofi asserted Orange Book-listed Multaq patent rights against Apotex.
• Apotex's ANDA and Paragraph IV certification created the statutory infringement dispute.
• The case ended without a reported public trial judgment determining that the entire Multaq patent estate was invalid.
• The termination of the case did not necessarily eliminate every patent or regulatory barrier to generic entry.
• Any launch date would have depended on the resolution terms, FDA approval, patent expiry, and other ANDA litigation involving competing applicants.

A confidential settlement is common in this type of litigation. Unless a settlement agreement is filed publicly or its terms are disclosed in an FTC review, the precise launch date, royalty provisions, licensing rights, and restrictions on generic entry should not be inferred from the docket alone.

Did Sanofi and Apotex enter a settlement agreement?

The case ended without a publicly reported merits decision that provides a complete description of the parties' commercial terms. The record does not establish a publicly available launch date, royalty structure, or license scope sufficient to reconstruct the entire settlement.

For pharmaceutical patent analysis, the important distinction is between:

• dismissal or termination of the case;
• dismissal pursuant to a confidential settlement;
• a license allowing an authorized generic or conventional ANDA launch; and
• a final judgment after trial.

Those outcomes have different implications for competition. A settlement can preserve patent protection while granting Apotex an agreed future entry date. It can also include restrictions concerning manufacturing, distribution, supply, or authorized-generic competition.

What was the Orange Book status of Multaq?

Multaq was listed in the Orange Book with patent protections covering the branded product and its use. The Orange Book listing supported Sanofi's ability to bring a Section 271(e)(2) action after receiving Apotex's Paragraph IV notice. [1]

Orange Book and regulatory implications

The Orange Book determines whether a patent is listed against an NDA and whether an ANDA applicant must address the listed patent through one of four certifications:

• Paragraph I: no patent information has been submitted;
• Paragraph II: the patent has expired;
• Paragraph III: the applicant will not market until patent expiration; or
• Paragraph IV: the patent is invalid, unenforceable, or not infringed.

For Multaq, the Paragraph IV route created the patent litigation in Delaware. FDA approval could not proceed during the statutory stay unless the litigation was resolved, the stay expired, or the court entered a decision permitting approval.

FDA approval and patent clearance were separate questions. Even if Apotex prevailed on a patent claim, it still needed to satisfy FDA requirements for bioequivalence, chemistry, manufacturing, controls, labeling, and facility compliance.

What generic entry risks did Apotex present to Sanofi?

Apotex represented a conventional ANDA threat rather than a biosimilar threat. Dronedarone is a chemically synthesized small molecule, so the relevant pathway was Section 505(j) of the Food, Drug, and Cosmetic Act, not the biologics license application and biosimilar pathway under the Public Health Service Act.

Principal generic-entry scenarios

Scenario	Effect on Sanofi
Sanofi wins on validity and infringement	Generic approval delayed until patent expiry or a licensed date
Apotex wins on noninfringement	FDA approval may proceed after regulatory requirements are met
Apotex invalidates the asserted patent	Earlier generic competition becomes possible
Confidential settlement	Entry occurs on an agreed date, subject to settlement terms
Apotex withdraws or delays its ANDA	Immediate competitive pressure is reduced
Other ANDA applicants enter separately	Multaq faces competition even if Apotex remains excluded

Generic entry would likely have affected both price and prescription volume. Antiarrhythmic products can face rapid substitution once multiple therapeutically equivalent products receive FDA approval and state substitution rules apply.

How strong was Sanofi's Multaq patent estate?

Sanofi's patent position was commercially meaningful but not unlimited.

Strengths

• Multaq had Orange Book-listed patent protection.
• A Paragraph IV certification enabled Sanofi to obtain a 30-month FDA approval stay.
• The asserted rights were directed to the branded drug's active ingredient, formulation, or therapeutic use.
• The case was resolved without a public invalidity judgment eliminating the asserted patents.

Weaknesses

• Earlier composition and use patents faced expiration pressure.
• Method-of-use claims can be vulnerable if the proposed generic label omits or carves out the patented indication.
• ANDA defendants can challenge claim construction, enablement, written description, obviousness, and infringement.
• Settlement-driven termination provides limited public evidence about the merits.
• Multaq's commercial protection depended on several separate patents and regulatory mechanisms rather than one perpetual right.

Patent strength should therefore be assessed claim by claim. The existence of an Orange Book listing is evidence of a litigation right, not proof that the listed claims would survive a validity challenge.

How did this case compare with biosimilar and generic patent litigation?

Sanofi v. Apotex was a small-molecule Hatch-Waxman case.

Issue	Sanofi v. Apotex	Biosimilar litigation
Product type	Small-molecule drug	Biologic
FDA pathway	ANDA under Section 505(j)	351(k) biosimilar application
Patent notice	Paragraph IV certification	Patent dance and related notices
Product comparison	Therapeutic equivalence and bioequivalence	Biosimilarity and interchangeability
Key patent risks	Composition, formulation, use, process	Composition, formulation, manufacturing, method, and platform patents
Regulatory stay	Hatch-Waxman 30-month stay	No identical automatic stay structure

The case did not create a biosimilar precedent and had no direct bearing on Sanofi's biologic products such as Dupixent, Lantus, or other biologic or insulin-related assets.

What was the commercial significance and revenue exposure?

Multaq's value was concentrated in the period before generic dronedarone could enter with FDA approval and unrestricted distribution. The case protected Sanofi from an immediate Apotex launch, but the economic value of the litigation depended on:

• Multaq's annual U.S. sales at the time;
• the number of competing ANDA filers;
• the agreed or legally available entry date;
• whether an authorized generic would be introduced;
• formulary treatment of generic dronedarone; and
• the number of remaining patent claims after the case ended.

A settlement that allowed entry before the latest patent expiry could materially reduce Sanofi's future revenue while avoiding the risk and cost of trial. A settlement that delayed entry until patent expiry would provide stronger protection but could face greater antitrust scrutiny if it included restrictions beyond the patent's legitimate scope.

Key Takeaways

• Sanofi-Aventis U.S. LLC v. Apotex Corp., No. 1:15-cv-00044, was a Delaware Hatch-Waxman case involving generic dronedarone, marketed as Multaq.
• Apotex's Paragraph IV certification triggered Sanofi's patent infringement action and the statutory FDA approval stay.
• U.S. Patent No. 8,410,167 was a principal Multaq patent associated with the dispute.
• The case ended without a publicly reported merits judgment invalidating Sanofi's complete Multaq patent estate.
• The public record does not provide a complete set of settlement terms or a definitive commercial launch schedule.
• The matter involved conventional generic competition, not biosimilar substitution.
• Multaq's competitive exposure depended on patent expiry, FDA approval, other ANDA challengers, and the terms of the parties' resolution.

FAQs About Sanofi-Aventis U.S. LLC v. Apotex Corp.

When could Apotex launch generic Multaq?

The public case record does not establish a definitive Apotex launch date. Entry depended on the resolution terms, FDA approval, and any remaining patent or regulatory barriers.

Did Apotex win the Multaq patent case?

There is no publicly reported final merits judgment establishing that Apotex invalidated the entire asserted Multaq patent estate. The case terminated after the active litigation ended.

Was Multaq subject to a 30-month FDA stay?

Yes. Sanofi's Section 271(e)(2) action following Apotex's Paragraph IV certification triggered the Hatch-Waxman framework, including the potential 30-month approval stay.

Were Multaq patents formulation patents or method-of-use patents?

The Multaq estate included rights directed to dronedarone compositions and therapeutic use. The precise scope depended on the claims asserted against Apotex's ANDA.

Could a Multaq generic be approved through the biosimilar pathway?

No. Dronedarone is a chemically synthesized small molecule. A generic version would proceed through the ANDA pathway, not the 351(k) biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book). FDA.
2. U.S. District Court for the District of Delaware. (2015-2017). Sanofi-Aventis U.S. LLC v. Apotex Corp., No. 1:15-cv-00044, docket materials.
3. United States Code. (2024). 35 U.S.C. § 271(e)(2).
4. United States Code. (2024). 21 U.S.C. § 355(j).
5. U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,410,167.